PONATINIB approved for leukemia in the European Union
Recently, ponatinib has obtained marketing authorization in the European Union (Iclusig, Ariad Pharmaceuticals), it can be used as an orphan drug for the treatment of resistant or intolerant to other some leukemia patients.
Specifically, ponatinib can be used for chronic phase, accelerated phase and blast phase chronic myeloid adult leukemia (CML) patients. These patients on dasatinib (SPRYCEL) / nilotinib (Tasigna) resistant or intolerant to imatinib or a (Gleevec) after treatment without appropriate clinical treatment, or the existence of the T315I mutation.
The study also showed that, ponatinib positive for Ph + acute lymphoblastic leukemia (ALL) patients, these patients dasatinib ALL resistant or intolerant, or by imatinib therapy without proper method, or the T315I mutation.
Ponatinib in December 2012 approved by the FDA for the above listed similar symptoms.
Ariad, who said that the EU Commission to expedite approval of a drug product listed ponatinib. This aims to speed up the approval for new drugs could benefit public health.
PONATINIB approved for leukemia in the European Union
ReplyDeleteRecently, ponatinib has obtained marketing authorization in the European Union (Iclusig, Ariad Pharmaceuticals), it can be used as an orphan drug for the treatment of resistant or intolerant to other some leukemia patients.
Specifically, ponatinib can be used for chronic phase, accelerated phase and blast phase chronic myeloid adult leukemia (CML) patients. These patients on dasatinib (SPRYCEL) / nilotinib (Tasigna) resistant or intolerant to imatinib or a (Gleevec) after treatment without appropriate clinical treatment, or the existence of the T315I mutation.
The study also showed that, ponatinib positive for Ph + acute lymphoblastic leukemia (ALL) patients, these patients dasatinib ALL resistant or intolerant, or by imatinib therapy without proper method, or the T315I mutation.
Ponatinib in December 2012 approved by the FDA for the above listed similar symptoms.
Ariad, who said that the EU Commission to expedite approval of a drug product listed ponatinib. This aims to speed up the approval for new drugs could benefit public health.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
GW 5074
AZ 628
ZM 336372
SP600125
CC-401 HCl
JNK-IN-8
AS 602801
SB 203580
SB 202190
Doramapimod